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Abstract  
Background:  
Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen related food 
allergy. We aimed to investigate the efficacy of one year AIT with the folding variant (FV) of 
recombinant (r) Bet v 1 on birch related soy allergy.  
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Methods:  
Out of 138 subjects with Bet v 1 sensitization, 82 were positive at double blind placebo 
controlled food challenge (DBPCFC) with soy. 56/82 were randomized 2:1 (active : placebo). Per 
protocol population (PPP) had received >150µg of allergen or placebo preparation. Outcome 
measures: lowest observed adverse effect levels (LOAEL), post interventional occurrence of 
objective signs (objS) at any dose level, sIgE/IgG4 against Bet v 1 and Gly m 4. Between-group 
changes were investigated (ANCOVA, Mann-Whitney-U-, Fisher exact test). 
Results: 
Baseline characteristics including LOAELs were comparable in both groups with objS and subjS 
occurring in 82% and 95% of active (n=38) versus 78% and 83% of placebo group (n=18). After 
AIT, objS occurred in 24% and 47%, respectively. LOAEL group differences showed a beneficial 
tendency (p=0.081) for LOAELobjective in PPP (30 verum, 15 placebo). sIgG4 raised only in active 
group (Bet v 1: p=0.054, Gly m 4: p=0.037), no relevant changes occurred for sIgE. Only 56% of 
the intended sample size was recruited. 
Conclusion: 
For the first time, we present data on the effect of rBet v 1-FV on birch related soy allergy. rBet v 
1-FV AIT induced significant immunogenic effects. Clinical assessment showed a tendency in 
favor of the active group but did not reach statistical significance.  
 
Keywords:  
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Frequently used abbreviations 
 
ab  - antibody 
AIT  - allergen immunotherapy 
ANCOVA - analysis of covariance 
BASALIT - Birch Associated Soy Allergy and Immuno-Therapy 
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CM  - challenge meal 
DBPCFC - Double blind placebo controlled food challenge 
FA  - food allergy 
FAS  - Full analysis set 
HASR  - Histamine adjusted soy reaction  
IQR  - Interquartile range 
LOAEL  - Lowest observed adverse effect level 
PPP  - Per protocol population 
QoL  - Quality of life 
SCIT  - Subcutaneous immunotherapy 
sIgE/G  - specific immunoglobulin E/G 
 
Introduction 
Sensitization to major birch pollen allergen Bet v 1 is often associated with pollen related food allergy 
(FA) [1] and birch related soy allergy became of growing importance during the last years [2-4]. The 
immunologic basis for birch pollen related FA results from IgE antibodies (ab) that are raised against 
major pollen allergens but that can also recognize homologous allergens belonging to the 
pathogenesis-related protein family 10, for example Gly m 4 in soybean [5-7]. 
There is still controversy as to whether pollen related FA can be successfully treated with allergen 
immunotherapy (AIT) with pollen allergens [8-11]. As birch pollen AIT was shown to induce Bet v 1 
specific (s) IgG4-ab that cross react with related food allergens and inhibit IgE binding by epitope 
competition, clinical effects of AIT on pollen related FA are to be expected [8,12]. 
Within previous investigations, birch pollen AIT with either sublingual (SLIT) or subcutaneous (SCIT) 
application, improved pollen related FA in some studies [13-17] while others could not confirm this 
[18-20]. The studies that reported improvement [13-17] were not placebo-controlled and did not 
include DBPCFC for endpoint assessment. The only existing randomized placebo-controlled trial 
investigated clinical effects of birch pollen AIT (single maximum dose 12.3µg Bet v 1/ml [21]) on birch 
related hazelnut FA by DBPCFC and was not able to detect group differences [19]. It was suggested, 
that doses to induce an appreciable effect of birch pollen AIT on pollen related FA should be higher 
than those sufficient to improve pollen related respiratory symptoms [16, 18, 21]. 
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Because of the growing number of affected patients and increasingly frequent reports on severe 
reactions [2-4,6], we decided to investigate the effect of rBet v 1-FV AIT (single maximum dose 
80µg/ml of Bet v 1/ml [22,23]) on birch related soy FA. The multicentric setting required previous 
standardization of  DBPCFC with soy [24].  
 
Methods 
Setting and patient selection 
Between 1/2010 and 2/2013, 195 adults (18 – 65 years) with history of birch pollen allergy were 
recruited in 16 centres (15 German, one Swiss). They underwent standardized allergy interview, skin 
prick test (SPT) as well as serum IgE test (see fig. 1). We defined eligibility for DBPCFC if patients had 
positive SPT for birch, ≥ 3.5kU/l of sIgE for birch allergen Bet v 1 and ≥ 0.7kU/l for its soy homologue 
Gly m 4 (ThermoFisher, Freiburg, Germany). The trial (EudraCT-Nr.: 2009-011737-27) was approved 
by the competent authorities in Germany and Switzerland; the leading ethic committee was located 
at University Medical Centre Leipzig (UMCL). All patients provided written informed consent. Main 
exclusion criteria were pregnancy and unstable asthma. The following drugs were contraindicated 
during AIT: Ongoing immunosuppression, long-term treatment with tranquilizers/psycho active 
drugs, betablocker, ongoing/previous anti-IgE therapy. The following drugs were allowed if needed: 
antihistamines, topical glucocorticosteroids, systemic glucocorticosteroids up to 7.5mg prednisolone 
equivalent ≤ 5 days. A sample size of 97 subjects (with randomization ratio 2:1) was regarded 
sufficient to reach a study power of ≥ 90%, based on lowest observed adverse effect levels for 
objective signs (LOAELobj) and subjective symptoms (LOAELsubj) as two primary endpoints without 
hierarchy. LOAELs (including their heterogeneity) as presented previously [4] were used for 
calculation of sample size, as well as clinically relevant group differences of 20g in LOAELobj, 10g in 
LOAELsubj and 15% non-compliance/drop-out rate. NCSS/ PASS software was applied. 
 
Skin prick test 
At baseline, SPT was performed with commercially available supplement free soy drinks (single prick 
to prick test, ALPRO, Uelzena, Germany) and with a panel of respiratory allergens including birch 
(Allergopharma GmbH & Co KG, Reinbek, Germany) for inclusion (cutoff  >/=3mm). Due to 
unexpected market withdrawal of the drink planned to be applied, only in case of comparable drinks 
used both before and following AIT, any reduction of wheal diameter at the end of treatment (as 
binary outcome) was analysed. Also, circle-approximated soy induced wheal area was divided by 
that induced by histamine (histamine adjusted soy reaction/HASR) in analogy to Dreborg [25].  
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Double blind placebo controlled food challenge 
Standardization of DBPCFC including composition of CM with consistent Gly m 4 levels was previously 
described [24, 26]. Single dose levels of soy protein were 0.0004 - 0.0044 - 0.05 - 0.15 - 0.5 - 1.5 - 2.5 
– 5 - 15g with a maximum cumulative dose of 24.7g protein. Investigators monitored 10 objective 
signs and patients recorded 8 subjective symptoms on 10cm visual analogue scales (VAS) each. 
DBPCFC was stopped after dose level 9 or if the patient showed any objective symptoms before.  
DBPCFC was defined positive if a patient presented at least one of the following reactions: 
>/=1 objective sign and/or >/=1 subjective symptoms (VAS value reaching 1.5cm or more and/or two 
or more subjective symptoms with single VAS values each reaching 0.5cm or more and summing up 
to 4cm or more in total) [24]. 
LOAELs corresponding to minimal reactive/threshold dose for objective signs and subjective 
symptoms were determined. In order to be able to detect any post interventional increase in 
symptom eliciting doses, we only included patients for AIT in whom DBPCFC was judged as positive at 
dose level 7 (single dose 2.5g, cumulative 4.7g soy protein) or below. Post interventional DBPCFC was 
performed within three months after end of AIT.  
 
Laboratory investigations 
sIgE- and sIgG4-ab were determined by using ImmunoCAP (Thermo Fisher Scientific, Freiburg, 
Germany). At screening, sIgE-ab against Bet v 1 and Gly m 4 were measured for inclusion. sIgE- and 
sIgG4-ab [27] against birch allergens Bet v 1, Bet v 2, soy extract, the soy allergens Gly m 4, Gly m 5, 
Gly m 6, frequent birch related food allergens Api g 1 (celery), Cor a 1 (hazelnut), Dau c 1 (carrot; 
made of equimolar ratio of Dau c 1.0104 and Dau c 1.0201), Mal d 1 (apple) and Pru av 1 (cherry) as 
well as sIgE against cross reacting carbohydrate determinants (MUXF3) were investigated at different 
time (t) points: t1 - at first injection, t2 - at end of up dosing, t3 at start of maintenance therapy, t4 at 
fourth dose, and t5 at last injection. Blood samples of all randomized subjects were shipped to Paul-
Ehrlich-Institut, Langen, Germany, and stored at -80°C until assayed. 
 
Investigational medical product and therapy  
The recombinant hypoallergenic derivative of the major birch pollen allergen rBet v 1-FV as well as the 
comparative placebo compound (both containing aluminium hydroxide, phenol, sodium chloride, sodium 
hydrogen carbonate) were manufactured by Allergopharma GmbH & Co. KG (Reinbek, Germany)  [22]. 
Patients were randomized to either active (rBet v 1-FV) or placebo intervention. Up-dosing of patients 
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started in 2010, 2011 or 2012 between July and October. The starting dose (strength A) was 0.75µg 
(0.15ml), continued with increasing dosages of 1.5/3.0/5µg (0.3/0.6/1.0ml) and then of 
10/20/40/80µg (0.1/0.2/0.4/0.8 ml of strength B). During up-dosing injections were administered at 
one weekly interval, with a maximum single dose of 80 µg. During prolongation, there were gradually 
increased injection intervals from 7-28 days. During maintenance, injections were applied every 28 
days with a 50% reduction during the birch pollen season. Asthma patients were monitored with 
peak flow at each trial injection. Patients of per protocol set population (PPP) had received a 
cumulative dose of at least 150µg major allergen (or placebo equivalent). 
  
Outcome measures 
Primary endpoints were DBPCFC-based LOAELs LOAELobj and LOAELsubj. Additionally, occurrence of 
any objective signs or subjective symptoms at post interventional DBPCFC was investigated. 
Secondary endpoints were (i) courses of sIgE- and sIgG4-ab levels for Bet v 1, Gly m 4 and other birch 
related foods from baseline to end of treatment, (ii) pre-post changes of reactivity at SPT (if suitable) 
as well as (iii) pre-post changes of FA related quality of life (QoL) via FA quality of life questionnaire – 
adult form (FAQLQ-AF) [28,29].  
 
Statistics  
The confirmatory analysis was based on the full analysis set (FAS) with baseline LOAEL instead of 
missing values at end of study if applicable and intention-to-treat principle. We focused on two 
primary endpoints without hierarchy - both LOAELobj and LOAELsubj since it was unclear in advance 
how many patients would react with objective signs at DBPCFC. Post-interventional measures after 
the ingestion of soy-containing CM were used in nonparametric analysis of covariance (ANCOVA) 
with corresponding baseline measures as covariates [30]. The global significance level of the clinical 
trial was limited to α=5%. The test-wise α-levels were adjusted for multiplicity according to the 
Bonferroni-Holm method [31] based on the ordered p values observed. The smaller observed p-values 
p(1) (corresponding with either LOAELobj or LOAELsubj) had to be lower than/equal to 
α(1)=αglobal/2=0.025≥p(1) to identify a significant treatment effect in at least one LOAEL. For the 2nd 
comparison p(2)≤α(2)=0.05 should be observed to establish significance in both endpoints. SAS 
macros developed and provided by the University of Göttingen within the German Research 
Foundation (DFG) sponsored project “Ordinal Data” were used to compare the treatments without any 
further covariates in confirmatory analysis. In a planned sensitivity analysis, the same procedures as in 
confirmatory analysis were applied within the per protocol population (PPP). Secondary and safety 
outcomes were analyzed by Fishers exact test, repeated-measures ANCOVA, and Mann-Whitney U 
test, with neither adjustment for multiplicity nor missing value imputations.  
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Results 
Characteristics of screening and study population 
195 patients (63.4% female, mean (SD) of age 38.1(12.8)) years were screened. 138 patients were 
eligible for DBPCFC, 82 (59.4%) had positive DBPCFC at baseline [24]. Out of those 82, 56 patients 
were randomized (2:1) to interventional AIT with rBet v 1-FV (n=38) or placebo (n=18) (figure 1). 
19/38 (50%) and 8/18 (44%) had a history of previous reactions to any soy product. 13/38 (34%) and 
8/18 (44%) underwent a previous AIT. Table 1 contains major characteristics of the trial population. 
54/56 randomised patients started the intervention, meaning that only 56% (54/97) of the intended 
sample size could be recruited within the given time frame. Major protocol violations occurred in 
9/54 subjects: in the active group, two subjects did not fulfil criteria for positive DBPCFC and in three 
other cumulative AIT allergen doses applied were below 150µg. In four subjects of active and two 
from placebo group no post interventional DBPCFC was performed. PPP included 45 subjects (for 
details see table 1). 
 
Allergen immunotherapy and adverse events 
Maintenance phase was reached in 31/37 (84%) patients of active and in 16/17 (94%) of placebo 
group. Cumulative allergen doses are given in table 1. During treatment course, 119 injection related 
adverse events (AE) occurred in 22/37 (60%) patients of the active and in 9/17 (53%) of the placebo 
group. AEs were almost exclusively mild: 64/119 (54%), consisted in localized injection site reactions, 
13/119 (11%) were skin reactions with generalized urticaria in one subject, 15/119 (13%) had 
respiratory (nose/lung; 3 asthmatic responses in 2 patients), 7/119 (6%) eye and 20/119 (17%) 
unspecific symptoms. There were no injection related serious AEs. During AIT, systemic intake of 
antihistamines was documented in 21/54 (39%) and of short-term systemic glucocorticosteroids in 
8/54 (15%) subjects (due to skin lesions in n=6 or asthma in n=2). 
 
Double blind placebo controlled food challenges  
At baseline, objective signs were present in 45/56 (80%): blistering/swelling of oral mucosa 47% 
(21/45), flush 18%, urticaria  2%  angioedema  7%, conjunctivitis 18%, rhinitis 18%, peakflow 
reduction 9%, heart rate increase 9%, drop of blood pressure 2%, gastrointestinal symptoms 
4%.Subjective symptoms occurred in 51/56 (91%, most frequently reported  were oral 
tingling/blistering 34% (19/56, dysphagia 23% and itching 14%.Nausea, abdominal pain and dizziness 
occurred in 7%, respectively, dyspnea in 4% and perceived lip swelling in 2%. Cumulative doses at 
occurrence of first symptoms and signs are shown in figure 2 and  DBPCFC-based outcome measures 
listedin table 2. No relevant dysbalances were seen between both groups at baseline with regard to 
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LOAELs, type of objective signs or type of subjective symptoms. 
In confirmatory analyses, in PPP (but not in FAS), LOAELobj tended to be higher in the active group 
(treated with rBet v 1-FV) compared with the placebo group (p=0.081). Individual dose level changes 
are shown in figure 3. With the best/worst case groups-related observations (regarding between-
group differences, heterogeneity and LOAELobj as exclusive primary endpoint) we calculated that 
between 81 and 162 patients (best/worst case scenario) would have been necessary to provide 
significant test results. A post interventional increase of one dose level or more occurred in 20/26 
(77%) subjects of active and in 9/14 (64%) subjects of placebo group who presented with objective 
signs both at baseline and post intervention.  
 
Skin prick test  
Maximum histamine induced wheal diameter at baseline was 5.0 mm [Interquartile range/IQR 
4.0;6.0] in active and 5.0 mm [3.9;5.4] in placebo group, with soy 6.8 mm [5.0;9.0] vs. 7.0 mm 
[3.9;8.6] and with birch 9.5 mm [7.0;10.5] vs. 8.0 mm [6.9;9.6], respectively. In the randomised 
population, the same type of soy drink at baseline and at control was used in 43/54 (80%) of 
subjects, and in PPP, in 26/30 (87%) of active and in 14/15 (93%) of placebo group. In PPP, there was 
a non-significant (p=0.116) shift toward reduced soy induced wheal diameter in active (6.0 mm) 
compared with placebo group (7.3 mm) at postinterventional SPT. HASR changed from 3.27 fold 
area (SD 4.48) at baseline to 1,57 fold (1.1) post intervention in the active, and from 2.33 fold (1.46) 
to 2.89 fold (3.71) in the placebo group, respectively.  No significant between-group differences 
were found, although a descriptive change toward smaller HASR were observed within the rBet v 1-
group compared to unchanged reactivity in the placebo group. 
 
Laboratory investigations 
At baseline, sIgE-ab > 0.35kU/l against Cor a 1, Dau c1, Mal d1, Pru av1 were detected in all subjects, 
against Api g 1 in 51/54, against soybean extract in 10/54, Bet v 2 in 5/54 and MUXF3 in 4/54. Low 
level Gly m 5 and Gly m 6 sIgE was seen exclusively in one patient (0.52 and 0.99kU/l, respectively). 
At baseline (t1), no relevant group differences were shown for any sIgE-ab investigated. In neither 
group, courses of sIgE-ab showed significant differences from t1 to t5 for Bet v 1, Gly m 4 or any 
other allergen investigated.  
 
In the active, but not in the placebo group, a significant increase from t1 to t5 for sIgG4-ab against 
Bet v 1 (figure 4a,b), Gly m 4 (figure 4c), Cor a 1 (figure 4d), Api g 1 (p<0.0001; respectively), Dau c1 
(p<0.001), Mal d 1 (p>0.006) and Pru av 1 (p<0.015) was found. When comparing post interventional 
t5 values, there was a significant increase of sIgG4-ab against Gly m 4 (p=0.037) and Cor a 1 (p=0.033) 
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in the active group; borderline significant increases occurred for sIgG4-ab against Bet v 1 (p=0.054), 
Bet v 2 (p=0.074), Pru av 1 (p=0.088) and Mal d 1 (p=0.06). No significant differences were seen for 
IgG4-ab against Gly m 5, Gly m 6, soybean extract, CCD, Api g1, Dau c 1. 
 
Quality of life 
FAQLQ-AF scores at baseline are given in table 1. No significant differences between active and 
placebo group were found with nearly unchanged post interventional scores. 
 
Discussion 
The BASALIT trial is the first randomized, double blind placebo controlled trial evaluating the efficacy 
of a component based birch pollen AIT on birch related soy FA in a multicentre setting. The 
immunologic basis for this type of FA results from Bet v 1 homologous soy allergen Gly m 4 which 
shows 53% amino acid sequence identity and 63% sequence peptide similarity to Bet v 1 [5,6].  
Subjects with combined Bet v 1 and Gly m 4 sensitization were included. Even though IgE values 
cannot safely predict reactivity at DBPCFC [32, 33] we initially decided to only include patients with 
defined IgE cut off values. The rBet v 1-FV extract was chosen for AIT as it shows low IgE-binding 
[22,23,34], was well tolerated in higher doses with no increase in adverse effects compared with the 
native extract and induced a significant increase in birch pollen sIgG4-ab [22,23,35]. 
A main limiting factor for investigations on FA is the availability of standardized CM with standardized 
allergen content to be used within DBPCFC. For this trial we set up standardized soy CM with 
consistent levels for protein contents and Gly m 4 levels [24,26]. Also, a standardized evaluation 
system was established [24]. Despite of intensified efforts, we only reached 56% of the intended 
sample size within the given time frame. 
The rBet v 1-FV extract was well tolerated and, as in previous trials [22, 35], the safety profile was 
comparable with placebo; no rBet v 1-FV related severe adverse effects occurred. Subjects of active 
group had received cumulative Bet v 1 allergen doses being eight to twenty fold higher compared 
with previous AIT studies on pollen related FA (i.e. 50µg [18] and 150µg [12]).    
LOAELobj at post interventional DBPCFC tended to be higher in active compared with placebo group 
in per protocol population. In detail, at baseline DBPCFC objective signs occurred in 82% of active 
versus 78% of placebo group and at post interventional DBPCFC in only 23% versus 47%. No 
significant differences were seen with regard to LOAELsubj or any overall occurrence of subjective 
symptoms between groups. Possibly, effects could have been more pronounced by applying higher 
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soy allergen doses, as only 80% of all subjects presented with objective signs at baseline DBPCFC. 
Allergen doses were comparable to those having been reported in a previous trial, where, however, 
another food matrix had been applied [4].  
 
In the active group, some subjects showed post interventional decrease of LOAEL while, remarkably, 
in the placebo group, a LOAEL increase was not rare (figure 3). One might speculate that there is a 
fluctuating course of the pollen related FA being influenced not only by birch pollen season but also 
by other clinical cofactors that might not have been fully eliminated at some time points of DBPCFC.  
In vitro investigations indicated an immunogenic effect of the rBet v 1-FV extract as there was a 
significant increase of Bet v 1 sIgG4-ab in active group which was more than twice as high as in 
previous trials using birch allergen extracts with lower Bet v 1 allergen levels [12,15]. Despite a 
significant increase of sIgG4-ab to all Bet v 1 homologues investigated we noticed significant 
between-group effects only for sIgG4-ab against Gly m 4 and Cor a 1. However, sIgG4-ab against Bet 
v 1, Bet v 2, Pru av 1 and Mal d 1 tended to be higher in rBet v 1-FV group.  
In accordance with our data, an increase of sIgG4-ab against Bet v 1 and Cor a 1 was demonstrated 
in another trial investigating the effect of one year whole extract birch pollen-SCIT in birch related 
hazelnut allergy [19]. Even though sIgG4-ab were expected to be functionally blocking, authors 
failed to show clinical improvement of hazelnut allergy after one year of treatment [19].  
In another recent trial, authors discussed that birch pollen-AIT may induce Bet v 1 sIgG4–ab that 
cross-react with related food allergens Mal d 1 and Cor a 1 and inhibit sIgE binding by epitope 
competition [12]. This effect was detectable after one year but was even stronger after three years 
of AIT (cumulative allergen dose 500µg) [12], and reduction in food allergen reactive sIgE-ab started 
only later than 12 months of AIT. Interestingly, sIgG4-ab were not simply IgE epitope identical as 
more than 35% of predicted IgE epitopes of Bet v 1, Mal d 1 and Cor a 1 were not recognized by 
sIgG4-ab. It was concluded that SCIT induced sIgG4-ab may not cover all IgE specificities [12].  
Due to unexpected market withdrawal, the soy drink being scheduled for baseline and control SPT 
was only available in a subgroup of patients. Therefore, we were not able to finally assess the 
influence of AIT on soy induced wheal diameter or on histamine adjusted wheal area [25, 36].  
Finally, in our trial, a rather small impact of birch related FA on QoL was measured which confirmed 
a previous single center experience [29].  
In summary, for the first time we present data on the effect of AIT with the major birch pollen 
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allergen Bet v 1 on birch pollen related FA to soy. This is the only study having investigated AIT 
induced changes in FA symptoms by means of standardized food challenge procedures and CM with 
consistent soy allergen levels [24,26]. One year SCIT with rBet v 1-FV showed a clear immunogenic 
effect on sIgE- and sIgG4-ab against Bet v 1 and Bet v 1 homologous food allergens. Clinical 
assessment showed a tendency in favor of the active group but did not reach statistical significance. 
One reason may be that the treatment period was too short to induce changes on relevant antibody 
levels, on epitopes or on clinical symptoms. Another reason lies in the fact that we failed to recruit 
the intended study sample size and, therefore, conclusive clinical results could not be reached. 
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Table 1  
 Active (rBet v 1-FV) group Placebo group 
 Randomized PPP Randomized PPP 
N (randomized/PPP) 38 30 18 15 
Sex female 25 (66%) 20 (67%) 12 (67%) 10 (67%)
Age (years) ++ 37.8 (14.6) 38.1 (15.0) 37.4 (13.8) 36.8 (13.6)
BMI (kg/m²)++ 24.5 (3.7) 24.2 (3.1) 23.8 (3.6) 23.6 (3.9)
SPT birch positive (baseline) 37 (97%) 29 (97%) 18 (100%) 15 (100%)
SPT soy positive (baseline) 36 (95%) 28 (93%) 16 (89%) 14 (93%)
Total IgE-ab  
(kU/L baseline) + 
163 
[74-375] 
153
[74-3] 
147
[67-242] 
136 
[71-220] 
Specific IgE-ab Bet v 1 (kU/L; 
baseline)+ 
34 
[17-66] 
34
[23-69] 
28
[16-64] 
30  
[16-73] 
Specific IgE-ab Gly m 4 
(kU/L; baseline)+ 
9 
[4-16] 
11
[5-16] 
6
[4-11] 
6 
[4-16] 
FAQLQ total score (baseline)
+ 
3.8 
[2.9-5.2] 
3.7
[2.8-5.2] 
3.8
[2.3-5.1] 
3.7 
[2.3-5.1] 
FAIM score 
(baseline) + 
3.2 
[2.7-4.2] 
3.1
[2.7-4.0] 
2.8
[2.3-3.8] 
2.7 
[2.3-3.3] 
Cumulative allergen dose at 
AIT (µg) + 
1013 
[99-1440] 
1031
[930-1120] 
1000* 
[960-1040] 
1013*
[960-1040] 
Number of visits during 
treatment+ 
21  
[20-23] 
22
[20-24] 
20
[20-22] 
21 
[20-22] 
 
Table 1: Characteristics of randomized patients/ per protocol population 
No significant differences were seen regarding patients’ characteristics and interventional courses 
between both investigational groups in either population (PPP – per protocol population); ++ 
mean(standard deviation); + median[interquartile range/IQR]), BMI – body mass index, AIT – allergen 
immunotherapy, SPT – skin prick test; *according calculated amount; FAQOL –food allergy quality of 
life; FAIM – food allergy independent measure 
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Table 2 
 Active (rBet v 1-FV) group Placebo group 
Baseline DBPCFC (n) 38 18 
Objective signs 82% 78% 
LOAELobj  4.7g [0.7-24.7] 2.2g [0.2-9.7] 
Subjective symptoms 95% 83% 
LOAELsubj 2.2g [0.7-4.7] 0.7g [0.2-2.2] 
Post interventional DBPCFC (n) 33 (of 37 treated) 15 (of 17 treated)
Objective signs 24% 47% 
LOAELobj 24.7g [24.7-24.7] 24.7g [2.2.-24.7]
Subjective symptoms 22/33 (67%) 9/15 (60%) 
LOAELsubj 4.7 g [0.7-24.7] 2.2g [2.2-24.7] 
Post interventional DBPCFC (n) in PPP 30 15 
Objective signs 23% 47% 
LOAELobj* 24.7g [24.7-24.7] 24.7g [2.2.-24.7]
LOAELsubj 7.2 g [0.7-24.7] 2.2g [2.2-24.7] 
 
Table 2: Double blind placebo controlled food challenge (DBPCFC)-related outcome measures  
Data presented for both interventional groups (including primary endpoints) with median values 
[interquartile range] of lowest observed adverse effect levels for objective signs and subjective 
symptoms (LOAELobj/subj); no significant group differences after SCIT (* in per protocol population 
[PPP] between-group effect for treatment with p-value =0.081) were observed. 
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Figure 3 (left) 
 
 
Figure 3 (right) 
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Fig 4a       Fig 4b 
 
Fig 4c       Fig 4d 
 
